Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-01-02
DOI
https://doi.org/10.3389/fimmu.2025.1634502
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

S. X. Li, Chen Wu, Xinfang Hou
Frontiers in Immunology
Gastric Cancer Management and Outcomes
article

Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

S. X. Li, Chen Wu, Xinfang Hou
article en

Abstract

No abstract available for this paper.
Frontiers in ImmunologyVol. 16
Zhengzhou University (CN), Henan Cancer Hospital (CN)
Good health and well-being
Openalex Percentile: Top 99%
Gastric Cancer Management and Outcomes
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial — S. X. Li, Chen Wu, et al. · Frontiers in Immunology (2026) | TGRS Research Map | TGRS